1887

Abstract

Inhibitors of the human immunodeficiency virus (HIV) protease are a promising class of antiviral agents that dramatically reduce HIV replication both in culture and in infected patients. However, as for many other antiviral compounds, long-term efficacy of these agents is impeded by the emergence of virus variants with increased resistance to their inhibitory action, following selection of specific mutations in the protease coding sequence. We have studied HIV-1 variants that emerged at different stages of selection in the presence of the C2-symmetrical protease inhibitor ABT-77003. The selection of variants was a gradual process during which mutations accumulated at different sites in the protease, generating virus populations with increasing levels of resistance to the drug. The initially selected viruses had a low level of resistance as well as a markedly reduced replicative capacity. Further accumulation of mutations at secondary sites led to an improvement in both drug resistance and replication. In spite of their reduced infectivity, partially selected virus populations did not readily revert to wild-type when serially passaged in drug-free conditions. Instead, even in the absence of drug, secondary mutations identical to those selected in the presence of the inhibitor continued to emerge. These mutations improved both the intrinsic replicative capacity of the virus and its level of resistance to the inhibitor, suggesting that once committed to drug resistance, readaptation of the enzyme to its natural substrate leads to a reduction of its sensitivity to the inhibitor.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-77-3-419
1996-03-01
2022-01-21
Loading full text...

Full text loading...

/deliver/fulltext/jgv/77/3/JV0770030419.html?itemId=/content/journal/jgv/10.1099/0022-1317-77-3-419&mimeType=html&fmt=ahah

References

  1. Charneau P., Alizon M., Clavel F. 1992; A second origin of plus strand synthesis is required for optimal HIV replication. Journal of Virology 66:2814–2820
    [Google Scholar]
  2. Coffin J. 1995; HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483–489
    [Google Scholar]
  3. Condra J., Schleie W., Blahy O., Ga Bryelski L., Graham D., Quintero J., Rhodes A., Hobbins H., Roth E., Shivaprakash M., Titus D., Yang T., Teppler H., Squires K., Deutsch P., Emini E. 1995; In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569–571
    [Google Scholar]
  4. Conlon C., Klenerman P., Edwards A., Larder B., Phillips R. 1994; Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. Journal of Infectious Diseases 169:411–415
    [Google Scholar]
  5. Danziani F., Antonelli G., Turriziani O., Riva E., Dong G., Bellarosa D. 1993; In vitro selection of human immunodeficiency virus type 1 resistant to Ro 31–8959 proteinase inhibitor. Antiviral Chemistry and Chemotherapy 4:335–339
    [Google Scholar]
  6. Debouck C. 1992; The HIV-1 protease as a therapeutic target for AIDS. AIDS Research and Human Retroviruses 8:153–164
    [Google Scholar]
  7. Doyon L., Poulin F., Pilots L., Clouette C., Thibeault D., Croteau G., Lamarrs D. 1995; Protease inhibitor resistant HIV-1 variants containing an altered protease cleavage site. Abstracts of the 2nd National Conference on Human Retroviruses, Washington, DC, USA, January 1995
    [Google Scholar]
  8. El-Farrash M., Kuroda M., Kitazaki T., Masuda T., Kato K., Hatanaka M., Harada S. 1994; Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor. Journal of Virology 68:233–239
    [Google Scholar]
  9. Harada S., Koyanagi Y., Yamamoto N. 1985; Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science 229:563–566
    [Google Scholar]
  10. Ho D., Toyoshima T., Mo H., Kempf D., Norbeck D., Chen C., Wideburg N., Burt S., Erickson J., Singh M. 1994; Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. Journal of Virology 68:2016–2020
    [Google Scholar]
  11. Ho D., Neumann A., Perelson A., Chen W., Leonard J., Markowitz M. 1995; Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123–126
    [Google Scholar]
  12. Hunter E. 1994; Macromolecular interactions in the assembly of HIV and other retroviruses. Seminars in Virology 5:71–83
    [Google Scholar]
  13. Kageyama S., Weinstein J., Shirasaka T., Kempf D., Norbeck D., Plattner J., Erickson J., Mitsuya H. 1992; In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combination. Antimicrobial Agents and Chemotherapy 36:926–933
    [Google Scholar]
  14. Kaplan A., Michael S., Wehbie R., Knigge M., Paul D., Everitt L., Kempf D., Norbeck D., Erickson J., Swanstrom R. 1994; Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proceedings of the National Academy of Sciences, USA 91:5597–5601
    [Google Scholar]
  15. Kempf D., Marsh K., Paul D., Knigge M., Norbeck D., Kohlbrenne R. W., Codacovi L., Vasavanonda S., Bryant P., Wang X. 1991; Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease. Antimicrobial Agents and Chemotherapy 35:2209–2214
    [Google Scholar]
  16. Kempf D., Codacovi L., Wang X., Kohlbrenner W., Wideburg N., Saldivar A., Vasavanonda S., Marsh K., Bryant P., Sham H., Green B., Betebenner B., Erickson J., Norbeck D. 1993; Symmetry-based inhibitors of HIV protease. Structure-activity studies of acylated 2, 4-diamino-1, 5-dipheny1-3-hydroxypentane and 2, 5-diamino-1, 6-diphenyl-3, 4-diol. Journal of Medicinal Chemistry 36:320–330
    [Google Scholar]
  17. Kohl N., Emini E., Schleif W., Davis L., Heimbach J., Dixon R., Scolnick E., Sigal I. 1988; Active human immunodeficiency virus protease is required for viral infectivity. Proceedings of the National Academy of Sciences, USA 85:4686–4690
    [Google Scholar]
  18. Kort J., Bilello J., Bauer G., Drusano G. 1993; Preclinical evaluation of antiviral activity and toxicity of Abbott A77003, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrobial Agents and Chemotherapy 37:115–119
    [Google Scholar]
  19. Krausslich H. G., Wimmer E. 1988; Viral proteinases. Annual Review of Biochemistry 54:701–754
    [Google Scholar]
  20. Lam P., Jadhav P., Eyermann C., Hodge C., Ru Y., Bacheler L., Meek J., Otto M., Rayner M., Wong Y., Chang C., Weber P., Jackson D., Sharpe T., Erickson-Viitanen S. 1994; Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science 263:380–384
    [Google Scholar]
  21. Lamarre D. 1995; Molecular basis of HIV-1 resistance to protease inhibitors. Structural flexibility of the protease and second-site compensatory mutations in cleavage sites. Abstracts of the 4th International Workshop on HIV Drug Resistance, Sardinia, Italy, 1995
    [Google Scholar]
  22. Loeb D. D., Swanstrom R., Everitt L., Manchester M., Stamper S.E., Hutchison C. A. 1989; Complete mutagenesis of the HIV-1 protease. Nature 340:397–400
    [Google Scholar]
  23. Markowitz M., Mo H., Kempf D., Norbeck D., Bhat T., Erickson J., Ho D. 1995; Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. Journal of Virology 69:701–706
    [Google Scholar]
  24. Masquelier B., Pellegrin L., Neau D., Legrand E., Paty M., Pellegrin J., Ragnaud J., Fleury H. 1995; A genotypic study of zidovudine and didanosine resistance in proviral DNA from patients with HIV-1 primary infection. Abstracts of the 2nd National Conference on Human Retroviruses, Washington, DC, USA, January 1995
    [Google Scholar]
  25. Miller M., Schneide R. J., Sathyanarayana B., Toth M., Marshall G., Clawson L., Selk L., Kent S., Wlodawer A. 1989; Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. Science 246:1149–1152
    [Google Scholar]
  26. Myers G., Wain-Hobson S., Henderson L., Korber B., Jeang K., Pavlakis G. (editors) 1994 Human Retroviruses and AIDS Los Alamos; Los Alamos National Laboratory:
    [Google Scholar]
  27. Najera L., Holguin A., Quinones-Mateu M., Munoz-Fernandez M., Najera R., Lopez-Galindez C., Domingo E. 1995; Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. Journal of Virology 69:23–31
    [Google Scholar]
  28. Navia M., Fitzgerald P., McKeever B., Leu C., Heimbach J., Herber W., Sigal I., Darke P., Springer J. 1989; Threedimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 337:615–620
    [Google Scholar]
  29. Otto M., Garber S., Winslow D., Reid C., Aldrich P., Jadhav P., Patterson C., Hodge C., Cheng Y. 1993; In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. Proceedings of the National Academy of Sciences, USA 90:7543–7547
    [Google Scholar]
  30. Patick A., Rose R., Greytock J., Bechtold C., Hermsmeier M., Chen P., Barrish J., Zahler R., Colonno R., Lin P. 1995; Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. Journal of Virology 69:2148–2152
    [Google Scholar]
  31. Pearl L., Taylor W. 1987; A structural model for the retroviral proteases. Nature 329:352–354
    [Google Scholar]
  32. Roberts N., Martin J., Kinchington D., Broadhurst A., Craig J., Duncan L., Galpin S., Handa B., Kay J., Krohn A., Lambert R., Merrett J., Mills J., Parkes K., Redshaw S., Ritchie A., Taylor D., Thomas G., Machin P. 1990; Rational design of peptide-based HIV proteinase inhibitors. Science 248:358–361
    [Google Scholar]
  33. Sardana V., Schlabach A., Graham P., Bush B., Condra J., Culberson J., Gotlib L., Graham D., Kohl N., Lafemina R. 1994; Human immunodeficiency virus type 1 protease inhibitors: evaluation of resistance engendered by amino acid substitutions in the enzyme’s substrate binding site. Biochemistry 33:2004–2010
    [Google Scholar]
  34. Vacca J., Dorsey B., Schleif W., Levin R., McDaniel S., Darke P., Zugay J., Quintero J., Blahy O., Roth E., Sardana V., Schlaback A., Graham P., Condra J., Gotlib L., Holloway L., Lin J., Chen L., Vastag K., Ostovic D., Anderson P., Emini E., Huff J. 1994; L-735, 524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proceedings of the National Academy of Sciences, USA 91:4096–4100
    [Google Scholar]
  35. Wain-Hobson S., Sonigo P., Danos O., Cole S., Alizon M. 1985; Nucleotide sequence of the AIDS virus, LAV. Cell 40:9–17
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-77-3-419
Loading
/content/journal/jgv/10.1099/0022-1317-77-3-419
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error